
|Videos|July 21, 2023
Key Retreatment Decisions in the Clinical Trials for Faricimab in nAMD
Author(s)Varun Chaudhary, MD, FRCS(C)
Dr Varun Chaudhary presents the retreatment decisions during the treat-and-extend phase of the TENAYA and LUCERNE clinical trials in neovascular AMD, focusing on the percentage of patients who maintained, extended, or reduced their treatment interval based on visual and anatomic criteria.
Advertisement
Episodes in this series
Newsletter
Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
Nanoscope Therapeutics releases positive long-term safety results from EXTEND study
2
4DMT releases positive interim 1.5- to 3.5-year data from phase 1/2 PRISM trial
3
Real-World Insights From Diagnosis to Treatment in Macular Telangiectasia Type 2 Care
4
Navigating the Gray Zone in MacTel Type 2: When to Treat Early or Advanced Disease
5


















































